Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study

Abstract Introduction Adalimumab is a monoclonal antibody that is used to treat autoimmune and inflammatory diseases. Biosimilars for adalimumab, including Hyrimoz, have been developed. We aimed to evaluate the effectiveness and adverse effects of Hyrimoz after switching. Methods The cohort consiste...

Full description

Bibliographic Details

Published in:	BMC Immunology
Main Authors:	W. H. A. van Poecke, N. E. F. Hooi, T. K. Mossel, M. A. W. Hermans, P. L. A. van Daele, E. M. Bunnik, Z. Brkic, L. K. Sels, A. A. H. J. Thiadens, P. M. van Hagen, J. A. M. van Laar, S. M. Rombach
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Subjects:	Flare adverse effects biosimilar adalimumab Hyrimoz Humira
Online Access:	https://doi.org/10.1186/s12865-025-00693-9